C1q (classical complement cascade initiator) is upregulated in AD brain and tags synapses for microglial phagocytosis via C3-CR3 signaling. This excessive, activity-independent pruning underlies early synaptic loss before plaque deposition. The hypothesis is supported by compelling mechanistic studies (Hong et al. 2016) and Annexon Pharmaceuticals' ANX005 antibody is in clinical development. The mechanism explains early cognitive decline independent of amyloid burden, addressing a critical therapeutic gap. However, the complement system has pleiotropic functions—C1q also mediates protective synaptic plasticity and immune defense. Timing is critical: blocking C1q in prodromal AD may prevent pruning while later intervention may disrupt essential CNS maintenance.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Complement C1Q Synaptic Tagging"]
B["C1QA C1QB C1QC Subcomponent Cascade"]
C["Microglial Phagocytosis Synapse Recognition"]
D["Early Synaptic Pruning"]
E["Cognitive Decline in Early AD"]
F["C1Q-Mediated Pruning as Driver"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations3 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
MECH 5CLIN 2GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
C1q mediates synapse loss in AD models; PMID 27488…
ANX005 (Annexon) in Phase I/II with acceptable safety profile
✗ Opposing Evidence
3
C1q has essential immune functions—systemic inhibition may increase infection risk
Complement inhibition may impair protective synaptic plasticity and CNS repair
Late-stage intervention unlikely to reverse established synaptic loss
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Legacy Pre-Pipeline Hypotheses: Neurodegeneration
Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease
Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.
This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.
IF prodromal AD patients (MCI due to AD, amyloid-positive) receive ANX005 (anti-C1q antibody) at 60mg/kg IV weekly for 12 months, THEN synaptic integrity markers in CSF (neurogranin, SNAP-25) will remain stable or increase compared to placebo-treated controls.
pendingconf: 0.72
Expected outcome: CSF neurogranin levels will remain within 10% of baseline in the ANX005 arm versus showing ≥15% increase (indicating synaptic loss) in the placebo arm within 12 months
Falsified by: Synaptic markers increase ≥15% in both ANX005 and placebo groups with no significant difference, indicating C1q blockade does not affect synaptic integrity in humans or the mechanism is not operative in prodromal AD
Method: Phase 2 randomized controlled trial (NCT05113966 or similar), n≥120 prodromal AD patients with biomarker-confirmed amyloid pathology, repeated CSF sampling at baseline and 12 months
IF early cognitive decline in AD is driven by C1q-mediated synaptic pruning independent of amyloid, THEN CSF C1q concentration will positively correlate with synaptic loss markers (neurogranin, GAP-43) and negatively correlate with cognitive scores (ADAS-Cog13) at baseline in amyloid-positive MCI patients, but show no correlation with amyloid PET standardized uptake value ratio.
pendingconf: 0.65
Expected outcome: Baseline CSF C1q will show r≥0.30 correlation with neurogranin and r≤-0.25 correlation with ADAS-Cog13, while showing r<0.10 correlation with amyloid PET SUVR in a cohort of ≥200 amyloid-positive MCI subjects
Falsified by: CSF C1q shows no significant correlation with synaptic markers (r<0.15) OR shows equal or stronger correlation with amyloid burden compared to synaptic markers, indicating amyloid rather than C1q drives cognitive decline
Method: Multicenter observational cohort study analyzing baseline CSF C1q (ELISA), synaptic biomarkers (neurogranin, GAP-43), amyloid PET imaging, and cognitive testing in amyloid-positive MCI participants from the Alzheimer's Clinical Trial Consortium or similar registry